PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 26639236-0 2016 10-Hydroxycamptothecin induces apoptosis in human neuroblastoma SMS-KCNR cells through p53, cytochrome c and caspase 3 pathways. 10-hydroxycamptothecin 0-22 tumor protein p53 Homo sapiens 87-90 27655499-8 2016 All the findings suggest that 10-HCPT can inhibit the formation of osteoclasts by reducing the expression of osteoclast-specific genes such as TRAP, CTSK and MMP-9. 10-hydroxycamptothecin 30-37 cathepsin K Mus musculus 149-153 27655499-8 2016 All the findings suggest that 10-HCPT can inhibit the formation of osteoclasts by reducing the expression of osteoclast-specific genes such as TRAP, CTSK and MMP-9. 10-hydroxycamptothecin 30-37 matrix metallopeptidase 9 Mus musculus 158-163 26821653-5 2016 The disruption of mitochondrial distribution, activation of the intracellular mitochondrial permeability transition pore, and release of cytochrome c during HCPT-induced apoptosis in dose and time-dependent manner indicate the involvement of mitochondria in BmN-SWU1 cells. 10-hydroxycamptothecin 157-161 cytochrome c Bombyx mori 137-149 26639236-0 2016 10-Hydroxycamptothecin induces apoptosis in human neuroblastoma SMS-KCNR cells through p53, cytochrome c and caspase 3 pathways. 10-hydroxycamptothecin 0-22 cytochrome c, somatic Homo sapiens 92-104 26639236-0 2016 10-Hydroxycamptothecin induces apoptosis in human neuroblastoma SMS-KCNR cells through p53, cytochrome c and caspase 3 pathways. 10-hydroxycamptothecin 0-22 caspase 3 Homo sapiens 109-118 26177829-8 2015 Meanwhile, down-regulation of RKIP induced an increase in the cell survival rate by inhibiting apoptosis induced by hydroxycamptothecine. 10-hydroxycamptothecin 116-136 phosphatidylethanolamine binding protein 1 Homo sapiens 30-34 26270258-10 2015 The combination of HCPT and DOX exhibited a synergistic effect as the nanosized HD NPs improved drug retention in drug-resistant cancer cells against P-gp efflux in MCF-7R cells. 10-hydroxycamptothecin 19-23 phosphoglycolate phosphatase Homo sapiens 150-154 26815184-1 2015 OBJECTIVE: To study the effect of 10-Hydroxycamptotbecine (10-HCPT) on the expression of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts (RASFs). 10-hydroxycamptothecin 59-66 vascular endothelial growth factor A Homo sapiens 89-123 26815184-1 2015 OBJECTIVE: To study the effect of 10-Hydroxycamptotbecine (10-HCPT) on the expression of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts (RASFs). 10-hydroxycamptothecin 59-66 vascular endothelial growth factor A Homo sapiens 125-129 26815184-7 2015 CONCLUSION: Compared with MTX, 10-HCPT showed significant effect on inhibiting the expression of VEGF in RASFs. 10-hydroxycamptothecin 31-38 vascular endothelial growth factor A Homo sapiens 97-101 24525588-2 2014 Three kinds of new cyclane-aminols were introduced into the structure of HCPT, which modified strong cytotoxic HCPT into cyclane-aminol HCPT analogs with moderate cytotoxicity and improved selectivity toward DNA topoisomerase I inhibition in tumor cells. 10-hydroxycamptothecin 73-77 DNA topoisomerase I Rattus norvegicus 208-227 25523336-0 2015 RPL13A as a reference gene for normalizing mRNA transcription of ovarian cancer cells with paclitaxel and 10-hydroxycamptothecin treatments. 10-hydroxycamptothecin 106-128 ribosomal protein L13a Homo sapiens 0-6 25523336-9 2015 The current study identified various reference genes suitable under different circumstances, while RPL13A was indicated to be the most suitable reference gene for analyzing the transcription profile of ovarian cancer cells following treatment with PTX and HCPT. 10-hydroxycamptothecin 256-260 ribosomal protein L13a Homo sapiens 99-105 25766079-2 2015 In this study, HCPT-loaded solid lipid nanoparticle (HCPT-loaded SLN) was successfully prepared. 10-hydroxycamptothecin 15-19 sarcolipin Homo sapiens 65-68 25766079-2 2015 In this study, HCPT-loaded solid lipid nanoparticle (HCPT-loaded SLN) was successfully prepared. 10-hydroxycamptothecin 53-57 sarcolipin Homo sapiens 65-68 25766079-3 2015 The HCPT-loaded SLN was characterized by size, entrapment efficiency and drug release manner. 10-hydroxycamptothecin 4-8 sarcolipin Homo sapiens 16-19 25766079-4 2015 The cytotoxicity of HCPT-loaded SLN was assessed in vitro using HepG2/HCPT cells and in vivo utilizing human tumor xenograft nude mouse model. 10-hydroxycamptothecin 20-24 sarcolipin Homo sapiens 32-35 25766079-6 2015 HCPT-loaded SLN enhanced the cytotoxicity of HCPT in a concentration-dependent manner. 10-hydroxycamptothecin 0-4 sarcolipin Homo sapiens 12-15 25766079-6 2015 HCPT-loaded SLN enhanced the cytotoxicity of HCPT in a concentration-dependent manner. 10-hydroxycamptothecin 45-49 sarcolipin Homo sapiens 12-15 25207865-2 2014 Herein, we report the construction of arginine-glycine-aspartic acid-cysteine (RGDC) tetrapeptide functionalized and 10-hydroxycamptothecin (HCPT)-encapsulated magnetic nanohybrids (RFHEMNs) for integrin alphaVbeta3-targeted drug delivery. 10-hydroxycamptothecin 117-139 integrin subunit alpha V Homo sapiens 195-215 25207865-2 2014 Herein, we report the construction of arginine-glycine-aspartic acid-cysteine (RGDC) tetrapeptide functionalized and 10-hydroxycamptothecin (HCPT)-encapsulated magnetic nanohybrids (RFHEMNs) for integrin alphaVbeta3-targeted drug delivery. 10-hydroxycamptothecin 141-145 integrin subunit alpha V Homo sapiens 195-215 24525588-2 2014 Three kinds of new cyclane-aminols were introduced into the structure of HCPT, which modified strong cytotoxic HCPT into cyclane-aminol HCPT analogs with moderate cytotoxicity and improved selectivity toward DNA topoisomerase I inhibition in tumor cells. 10-hydroxycamptothecin 111-115 DNA topoisomerase I Rattus norvegicus 208-227 18318465-1 2008 A beta-glucuronidase-activated prodrug approach was applied to 10-hydroxycamptothecin, a Camptotheca alkaloid with promising antitumor activity but poor water solubility. 10-hydroxycamptothecin 63-85 glucuronidase beta Homo sapiens 2-20 24530519-2 2014 This dendrimer was able to tightly encapsulate the hydrophobic anticancer drug 10-hydroxycamptothecin (10-HCPT) through simple complexation and selectively target the drug to cancer cells overexpressing integrin alphavbeta3 through high affinity interactions. 10-hydroxycamptothecin 79-101 integrin subunit alpha V Homo sapiens 203-223 24530519-2 2014 This dendrimer was able to tightly encapsulate the hydrophobic anticancer drug 10-hydroxycamptothecin (10-HCPT) through simple complexation and selectively target the drug to cancer cells overexpressing integrin alphavbeta3 through high affinity interactions. 10-hydroxycamptothecin 103-110 integrin subunit alpha V Homo sapiens 203-223 24660962-2 2014 In this paper, we report on a self-assembling supramolecular nanostructure of D-amino acid-based peptide Nap-G(D)F(D)F(D)YGRGD (D-fiber, (D)F meant D-phenylalanine, (D)Y meant D-tyrosine), which were used as carriers for 10-hydroxycamptothecin (HCPT). 10-hydroxycamptothecin 221-243 catenin beta like 1 Homo sapiens 105-108 24660962-2 2014 In this paper, we report on a self-assembling supramolecular nanostructure of D-amino acid-based peptide Nap-G(D)F(D)F(D)YGRGD (D-fiber, (D)F meant D-phenylalanine, (D)Y meant D-tyrosine), which were used as carriers for 10-hydroxycamptothecin (HCPT). 10-hydroxycamptothecin 245-249 catenin beta like 1 Homo sapiens 105-108 23569373-0 2013 Preparation of 10-hydroxycamptothecin-loaded glycyrrhizic acid-conjugated bovine serum albumin nanoparticles for hepatocellular carcinoma-targeted drug delivery. 10-hydroxycamptothecin 15-37 albumin Homo sapiens 81-94 23569373-6 2013 Characteristics of 10-hydroxycamptothecin-loaded glycyrrhizic acid-conjugated bovine serum albumin nanoparticles (GL-BSA-HCPT-NPs), such as the drug encapsulation efficiency, drug loading efficiency, and GL-BSA content were studied. 10-hydroxycamptothecin 19-41 albumin Homo sapiens 85-98 22160573-1 2012 In this work, fluorescence spectroscopy in combination with circular dichroism spectroscopy and molecular modeling was employed to investigate the binding of 10-hydroxycamptothecin (HCPT) to human serum albumin (HSA) under simulative physiological conditions. 10-hydroxycamptothecin 158-180 albumin Homo sapiens 212-215 22160573-1 2012 In this work, fluorescence spectroscopy in combination with circular dichroism spectroscopy and molecular modeling was employed to investigate the binding of 10-hydroxycamptothecin (HCPT) to human serum albumin (HSA) under simulative physiological conditions. 10-hydroxycamptothecin 182-186 albumin Homo sapiens 212-215 22160573-2 2012 The experiment results showed that the fluorescence quenching of HSA by HCPT was a result of the formation of HCPT-HSA complex. 10-hydroxycamptothecin 72-76 albumin Homo sapiens 65-68 22160573-2 2012 The experiment results showed that the fluorescence quenching of HSA by HCPT was a result of the formation of HCPT-HSA complex. 10-hydroxycamptothecin 72-76 albumin Homo sapiens 115-118 22160573-3 2012 The corresponding association constants (K (a)) between HCPT and HSA at four different temperatures were determined according to the modified Stern-Volmer equation. 10-hydroxycamptothecin 80-84 albumin Homo sapiens 89-92 22160573-4 2012 The results of thermodynamic parameters DeltaG, DeltaH, and DeltaS indicated that hydrogen bonds and van der Waals forces played major roles for HCPT-HSA association. 10-hydroxycamptothecin 145-149 albumin Homo sapiens 150-153 22160573-5 2012 Site marker competitive displacement experiment indicated that the binding of HCPT to HSA primarily took place in sub-domain IIA (site I). 10-hydroxycamptothecin 78-82 albumin Homo sapiens 86-89 22160573-7 2012 The conformational investigation showed that the presence of HCPT decreased the alpha-helical content of HSA and induced the slight unfolding of the polypeptides of protein, which confirmed some micro-environmental and conformational changes of HSA molecules. 10-hydroxycamptothecin 61-65 albumin Homo sapiens 105-108 22160573-7 2012 The conformational investigation showed that the presence of HCPT decreased the alpha-helical content of HSA and induced the slight unfolding of the polypeptides of protein, which confirmed some micro-environmental and conformational changes of HSA molecules. 10-hydroxycamptothecin 61-65 albumin Homo sapiens 245-248 22320884-6 2012 MARVELD1 overexpression could enhance chemosensitivity of HCC cells to epirubicin and 10-hydroxycamptothecin. 10-hydroxycamptothecin 86-108 MARVEL domain containing 1 Homo sapiens 0-8 22051412-1 2012 In this study, the binding interactions of the water-soluble camptothecin derivatives hydroxycamptothecin (10-HCPT), topotecan (TPT), and camptothecin quaternary salt (CPT8), to bovine serum albumin (BSA) were determined using fluorescence spectra and UV-vis spectra. 10-hydroxycamptothecin 107-114 albumin Homo sapiens 185-198 21435100-3 2011 In the present study we investigate the hypothesis that the unique water dispersible oleic acid-Triton X-100-coated Fe3O4 nanoparticles loaded with HCPT disrupt epithelial cell-cell junctions and induce human lung cancer cell apoptosis through the caspase-8 pathway. 10-hydroxycamptothecin 148-152 caspase 8 Homo sapiens 248-257 21435100-6 2011 HCPT-loaded nanoparticles reduced the expression of cell-cell junction protein claudins, E-cadherin and ZO-1, and transmission electron microcopy demonstrated a disrupted tight junction ultrastructure. 10-hydroxycamptothecin 0-4 cadherin 1 Homo sapiens 89-99 21435100-6 2011 HCPT-loaded nanoparticles reduced the expression of cell-cell junction protein claudins, E-cadherin and ZO-1, and transmission electron microcopy demonstrated a disrupted tight junction ultrastructure. 10-hydroxycamptothecin 0-4 tight junction protein 1 Homo sapiens 104-108 21435100-8 2011 The HCPT-loaded nanoparticles increased phosphorylation of p38 and SAPK/JNK while it showed no effects on p42/44 MAP kinase. 10-hydroxycamptothecin 4-8 mitogen-activated protein kinase 14 Homo sapiens 59-62 21435100-8 2011 The HCPT-loaded nanoparticles increased phosphorylation of p38 and SAPK/JNK while it showed no effects on p42/44 MAP kinase. 10-hydroxycamptothecin 4-8 mitogen-activated protein kinase 9 Homo sapiens 67-71 21435100-8 2011 The HCPT-loaded nanoparticles increased phosphorylation of p38 and SAPK/JNK while it showed no effects on p42/44 MAP kinase. 10-hydroxycamptothecin 4-8 mitogen-activated protein kinase 9 Homo sapiens 72-75 21435100-9 2011 Compared with void Fe3O4 nanoparticles or HCPT drug alone, HCPT drug-loaded nanoparticles evoked synergistic effects by increasing cell apoptosis with enhanced activation of the caspase-8 pathway. 10-hydroxycamptothecin 59-63 caspase 8 Homo sapiens 178-187 20810290-0 2010 Experimental evaluation of inhibitory effect of 10-hydroxycamptothecin on hypoxia-inducible factor-1alpha expression and angiogenesis in liver tumors after transcatheter arterial embolization. 10-hydroxycamptothecin 48-70 hypoxia-inducible factor 1-alpha Oryctolagus cuniculus 74-105 20810290-1 2010 PURPOSE: To evaluate the effect of transcatheter administration of 10-hydroxycamptothecin (HCPT), a hypoxia-inducible factor-1alpha (HIF-1alpha) inhibitor, on HIF-1alpha expression and angiogenesis in liver tumors after transcatheter arterial embolization in an animal model. 10-hydroxycamptothecin 67-89 hypoxia-inducible factor 1-alpha Oryctolagus cuniculus 100-131 20810290-1 2010 PURPOSE: To evaluate the effect of transcatheter administration of 10-hydroxycamptothecin (HCPT), a hypoxia-inducible factor-1alpha (HIF-1alpha) inhibitor, on HIF-1alpha expression and angiogenesis in liver tumors after transcatheter arterial embolization in an animal model. 10-hydroxycamptothecin 67-89 hypoxia-inducible factor 1-alpha Oryctolagus cuniculus 133-143 20810290-1 2010 PURPOSE: To evaluate the effect of transcatheter administration of 10-hydroxycamptothecin (HCPT), a hypoxia-inducible factor-1alpha (HIF-1alpha) inhibitor, on HIF-1alpha expression and angiogenesis in liver tumors after transcatheter arterial embolization in an animal model. 10-hydroxycamptothecin 67-89 hypoxia-inducible factor 1-alpha Oryctolagus cuniculus 159-169 20810290-1 2010 PURPOSE: To evaluate the effect of transcatheter administration of 10-hydroxycamptothecin (HCPT), a hypoxia-inducible factor-1alpha (HIF-1alpha) inhibitor, on HIF-1alpha expression and angiogenesis in liver tumors after transcatheter arterial embolization in an animal model. 10-hydroxycamptothecin 91-95 hypoxia-inducible factor 1-alpha Oryctolagus cuniculus 100-131 20810290-1 2010 PURPOSE: To evaluate the effect of transcatheter administration of 10-hydroxycamptothecin (HCPT), a hypoxia-inducible factor-1alpha (HIF-1alpha) inhibitor, on HIF-1alpha expression and angiogenesis in liver tumors after transcatheter arterial embolization in an animal model. 10-hydroxycamptothecin 91-95 hypoxia-inducible factor 1-alpha Oryctolagus cuniculus 159-169 20810290-12 2010 CONCLUSIONS: Transcatheter infusion of HCPT has an inhibitory effect on HIF-1alpha expression and angiogenesis in liver tumors after transcatheter arterial embolization. 10-hydroxycamptothecin 39-43 hypoxia-inducible factor 1-alpha Oryctolagus cuniculus 72-82 21499429-0 2011 Preparation, characterization and targeting of micronized 10-hydroxycamptothecin-loaded folate-conjugated human serum albumin nanoparticles to cancer cells. 10-hydroxycamptothecin 58-80 albumin Homo sapiens 112-125 17482779-0 2007 Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. 10-hydroxycamptothecin 73-95 albumin Rattus norvegicus 117-130 17482779-0 2007 Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. 10-hydroxycamptothecin 97-101 albumin Rattus norvegicus 117-130 14751837-6 2003 The antisense oligonucleotides also potentiated the effects of p53 activation and p21 induction by chemotherapeutic agents 10-hydroxycamptothecin, adriamycin, 5-fluorouracil, and paclitaxel. 10-hydroxycamptothecin 123-145 H3 histone pseudogene 16 Homo sapiens 82-85 16603448-0 2006 Bcl-2 siRNA induced apoptosis and increased sensitivity to 5-fluorouracil and HCPT in HepG2 cells. 10-hydroxycamptothecin 78-82 BCL2 apoptosis regulator Homo sapiens 0-5 16603448-7 2006 Accordingly, Bax protein expression had no change and caspase-3 protein expression showed significantly be up regulated; (2) MTT results showed that Bcl-2 siRNA transfectants had higher cell inhibitory rates after treated with 5-FU or HCPT; (3) flow cytometry results demonstrated that sub G1 population increased in Bcl-2 siRNA transfected cells compared with negative siRNA or untreated cells. 10-hydroxycamptothecin 235-239 BCL2 apoptosis regulator Homo sapiens 149-154 16603448-8 2006 After addition 5-FU (1300 mg/l) and HCPT (0.72 mg/l), Bcl-2 siRNA cells showed higher sub G1 population than negative siRNA or untreated cells. 10-hydroxycamptothecin 36-40 BCL2 apoptosis regulator Homo sapiens 54-59 16603448-9 2006 siRNA targeting Bcl-2 gene can specifically down-regulate Bcl-2 expression, increased Bax/Bcl-2 ratio expression and caspase-3 activity in HepG2 cells, which lead to increase cells spontaneous apoptosis and sensitize cells to 5-FU or HCPT. 10-hydroxycamptothecin 234-238 BCL2 apoptosis regulator Homo sapiens 16-21 16084097-1 2005 We have synthesized a conjugate of cis-4,7,10,13,16,19-docosahexenoic acid (DHA) and 10-hydroxycamptothecin (HCPT), DHA-HCPT. 10-hydroxycamptothecin 85-107 suppressor of cytokine signaling 6 Mus musculus 35-40 17439414-10 2007 The MTT results demonstrated that Bcl-2 and Bcl-xl transfected cells exhibited increased sensitivity to 5-FU or HCPT. 10-hydroxycamptothecin 112-116 BCL2 apoptosis regulator Homo sapiens 34-39 17439414-10 2007 The MTT results demonstrated that Bcl-2 and Bcl-xl transfected cells exhibited increased sensitivity to 5-FU or HCPT. 10-hydroxycamptothecin 112-116 BCL2 like 1 Homo sapiens 44-50 12518324-7 2003 The antisense oligonucleotide also potentiated the effects of p53 activation and p21 induction by chemotherapeutic agents 10-hydroxycamptothecin, adriamycin, 5-fluorouracil, and paclitaxel. 10-hydroxycamptothecin 122-144 H3 histone pseudogene 16 Homo sapiens 81-84 13130078-7 2003 In all three cell lines, MDM2 inhibition reduced cell proliferation, induced apoptosis, and potentiated the effects of the chemotherapeutic agents 10-hydroxycamptothecin and paclitaxel. 10-hydroxycamptothecin 147-169 MDM2 proto-oncogene Homo sapiens 25-29 11324469-5 2000 RESULTS: After treatment with HCPT at differentiation-inducing concentrations 5-20 micrograms.L-1 for 6 d, Hep G2 cells were mainly arrested at G2/M phase and the PCNA expression rate was lower than that of control cells. 10-hydroxycamptothecin 30-34 proliferating cell nuclear antigen Homo sapiens 163-167 11129738-0 2000 Differential regulation of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase activity during 10-hydroxycamptothecin-induced apoptosis in Hep G2 cells. 10-hydroxycamptothecin 106-128 alpha fetoprotein Homo sapiens 54-57 11129738-3 2000 It showed that HCPT at a dose of 0.1 microg/ml increased the expression of P53, c-Myc and Bax protein, and decreased the expression of Bcl-2 and AFP. 10-hydroxycamptothecin 15-19 tumor protein p53 Homo sapiens 75-78 11129738-3 2000 It showed that HCPT at a dose of 0.1 microg/ml increased the expression of P53, c-Myc and Bax protein, and decreased the expression of Bcl-2 and AFP. 10-hydroxycamptothecin 15-19 MYC proto-oncogene, bHLH transcription factor Homo sapiens 80-85 11129738-3 2000 It showed that HCPT at a dose of 0.1 microg/ml increased the expression of P53, c-Myc and Bax protein, and decreased the expression of Bcl-2 and AFP. 10-hydroxycamptothecin 15-19 BCL2 associated X, apoptosis regulator Homo sapiens 90-93 11129738-3 2000 It showed that HCPT at a dose of 0.1 microg/ml increased the expression of P53, c-Myc and Bax protein, and decreased the expression of Bcl-2 and AFP. 10-hydroxycamptothecin 15-19 BCL2 apoptosis regulator Homo sapiens 135-140 11129738-3 2000 It showed that HCPT at a dose of 0.1 microg/ml increased the expression of P53, c-Myc and Bax protein, and decreased the expression of Bcl-2 and AFP. 10-hydroxycamptothecin 15-19 alpha fetoprotein Homo sapiens 145-148 11129738-4 2000 The increase of P53, which was remarkable after only 3 h incubation with HCPT, occurred much earlier than the changes of other proteins, suggesting that the increase of P53 expression may be the upstream event in the apoptosis of Hep G2 cells induced by HCPT. 10-hydroxycamptothecin 73-77 tumor protein p53 Homo sapiens 16-19 11129738-4 2000 The increase of P53, which was remarkable after only 3 h incubation with HCPT, occurred much earlier than the changes of other proteins, suggesting that the increase of P53 expression may be the upstream event in the apoptosis of Hep G2 cells induced by HCPT. 10-hydroxycamptothecin 254-258 tumor protein p53 Homo sapiens 16-19 11129738-4 2000 The increase of P53, which was remarkable after only 3 h incubation with HCPT, occurred much earlier than the changes of other proteins, suggesting that the increase of P53 expression may be the upstream event in the apoptosis of Hep G2 cells induced by HCPT. 10-hydroxycamptothecin 254-258 tumor protein p53 Homo sapiens 169-172 11129738-5 2000 Both caspase-1 and caspase-3 were activated in Hep G2 cells by HCPT treatment, suggesting that caspase-1 and caspase-3 are involved in the process of apoptosis in Hep G2 cells, and may be the main effectors of the apoptosis. 10-hydroxycamptothecin 63-67 caspase 1 Homo sapiens 5-14 11129738-5 2000 Both caspase-1 and caspase-3 were activated in Hep G2 cells by HCPT treatment, suggesting that caspase-1 and caspase-3 are involved in the process of apoptosis in Hep G2 cells, and may be the main effectors of the apoptosis. 10-hydroxycamptothecin 63-67 caspase 3 Homo sapiens 19-28 11129738-5 2000 Both caspase-1 and caspase-3 were activated in Hep G2 cells by HCPT treatment, suggesting that caspase-1 and caspase-3 are involved in the process of apoptosis in Hep G2 cells, and may be the main effectors of the apoptosis. 10-hydroxycamptothecin 63-67 caspase 1 Homo sapiens 95-104 11129738-5 2000 Both caspase-1 and caspase-3 were activated in Hep G2 cells by HCPT treatment, suggesting that caspase-1 and caspase-3 are involved in the process of apoptosis in Hep G2 cells, and may be the main effectors of the apoptosis. 10-hydroxycamptothecin 63-67 caspase 3 Homo sapiens 109-118 11324469-6 2000 When Hep G2 cells grew in a medium containing HCPT 5 micrograms.L-1 for 6 d, the p53 expression level markedly increased in comparison with the control cells. 10-hydroxycamptothecin 46-50 tumor protein p53 Homo sapiens 81-84 8010056-0 1993 Inhibition of phosphorylation of histone H1 and H3 induced by 10-hydroxycamptothecin, DNA topoisomerase I inhibitor, in murine ascites hepatoma cells. 10-hydroxycamptothecin 62-84 topoisomerase (DNA) I Mus musculus 86-105 9499438-0 1998 Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. 10-hydroxycamptothecin 149-171 cyclin dependent kinase inhibitor 1A Homo sapiens 16-28 9499438-0 1998 Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. 10-hydroxycamptothecin 149-171 tumor protein p53 Homo sapiens 197-200 9499438-3 1998 Using various DNA fragmentation analyses and the terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assay, the apoptosis induced by HCPT and CPT was shown to be dose- and time-dependent. 10-hydroxycamptothecin 154-158 DNA nucleotidylexotransferase Homo sapiens 49-86 9499438-6 1998 The levels of p53 and p21WAF1/CIP1 protein increased in MCF-7 cells treated with HCPT or CPT in a dose- and time-dependent manner. 10-hydroxycamptothecin 81-85 tumor protein p53 Homo sapiens 14-17 9499438-6 1998 The levels of p53 and p21WAF1/CIP1 protein increased in MCF-7 cells treated with HCPT or CPT in a dose- and time-dependent manner. 10-hydroxycamptothecin 81-85 cyclin dependent kinase inhibitor 1A Homo sapiens 30-34 9499438-7 1998 The levels of p21WAF1/CIP1 protein also increased in a dose- and time-dependent manner in MDA-MB-468 cells treated with HCPT or CPT, whereas the mutated p53 protein levels had no significant change. 10-hydroxycamptothecin 120-124 cyclin dependent kinase inhibitor 1A Homo sapiens 22-26 9499438-10 1998 Using Northern blot analysis, the transcription of p21WAF1/CIP1 was shown to increase in a dose-dependent manner in MCF-7 and MDA-MB-468 cells treated with HCPT or CPT. 10-hydroxycamptothecin 156-160 cyclin dependent kinase inhibitor 1A Homo sapiens 59-63 9499438-11 1998 These results suggest that treatment with HCPT and CPT results in increased levels of p21WAF1/CIP1 protein and mRNA, and that they induce apoptosis in human breast cancer cells through both p53-dependent and -independent pathways. 10-hydroxycamptothecin 42-46 cyclin dependent kinase inhibitor 1A Homo sapiens 94-98 9499438-11 1998 These results suggest that treatment with HCPT and CPT results in increased levels of p21WAF1/CIP1 protein and mRNA, and that they induce apoptosis in human breast cancer cells through both p53-dependent and -independent pathways. 10-hydroxycamptothecin 42-46 tumor protein p53 Homo sapiens 190-193 7766631-10 1995 The stability of 10-hydroxycamptothecin-induced cleavable complexes was intermediate to those of CPT and SN-38, indicating that both the 10-hydroxy and the 7-ethyl group of SN-38 probably interact with the drug binding site of top1-cleavable complexes. 10-hydroxycamptothecin 17-39 choline phosphotransferase 1 Homo sapiens 97-100 32061620-3 2020 Here we fabricated a tumor microenvironment-activated self-targeting nanodrug, via co-assembly of hydroxycamptothecin (HCPT) and bi-functional methotrexate (MTX, not only has antitumor effect but also shows innate affinity towards folate receptors) followed by surface covering through acidity-responsive polyethylene glycol (PEG). 10-hydroxycamptothecin 98-117 metaxin 1 Homo sapiens 157-160 33104985-6 2021 Compared with the control group, the expressions of key regulators of oocyte apoptosis (bax, caspase-3) and autophagy (lc3, beclin, ATG12) pathway were increased in the HCPT-treated group. 10-hydroxycamptothecin 169-173 BCL2-associated X protein Mus musculus 88-91 33104985-6 2021 Compared with the control group, the expressions of key regulators of oocyte apoptosis (bax, caspase-3) and autophagy (lc3, beclin, ATG12) pathway were increased in the HCPT-treated group. 10-hydroxycamptothecin 169-173 caspase 3 Mus musculus 93-102 33104985-6 2021 Compared with the control group, the expressions of key regulators of oocyte apoptosis (bax, caspase-3) and autophagy (lc3, beclin, ATG12) pathway were increased in the HCPT-treated group. 10-hydroxycamptothecin 169-173 microtubule-associated protein 1 light chain 3 alpha Mus musculus 119-122 33104985-6 2021 Compared with the control group, the expressions of key regulators of oocyte apoptosis (bax, caspase-3) and autophagy (lc3, beclin, ATG12) pathway were increased in the HCPT-treated group. 10-hydroxycamptothecin 169-173 autophagy related 12 Mus musculus 132-137 34968801-7 2022 RNA interference assay showed that 10-HCPT inhibited PRV replication by targeting DNA topoisomerase 1 (TOP1). 10-hydroxycamptothecin 35-42 DNA topoisomerase I Homo sapiens 82-101 34968801-7 2022 RNA interference assay showed that 10-HCPT inhibited PRV replication by targeting DNA topoisomerase 1 (TOP1). 10-hydroxycamptothecin 35-42 DNA topoisomerase I Homo sapiens 103-107 33427515-2 2021 The expression of hypoxia-inducible factor-1alpha (HIF-1alpha) is reportedly upregulated in liver cancer tissues, which is directly linked to the resistance of 10-HCPT. 10-hydroxycamptothecin 160-167 hypoxia inducible factor 1 subunit alpha Homo sapiens 18-49 33427515-2 2021 The expression of hypoxia-inducible factor-1alpha (HIF-1alpha) is reportedly upregulated in liver cancer tissues, which is directly linked to the resistance of 10-HCPT. 10-hydroxycamptothecin 160-167 hypoxia inducible factor 1 subunit alpha Homo sapiens 51-61 33381022-15 2020 In addition, miR-433 upregulated the expression of Cdk12 and inhibited cell proliferation in a Cdk12-dependent manner and promoted apoptosis in HT-22 cells under the treatment of 10-hydroxycamptothecin. 10-hydroxycamptothecin 179-201 microRNA 433 Mus musculus 13-20 33381022-15 2020 In addition, miR-433 upregulated the expression of Cdk12 and inhibited cell proliferation in a Cdk12-dependent manner and promoted apoptosis in HT-22 cells under the treatment of 10-hydroxycamptothecin. 10-hydroxycamptothecin 179-201 cyclin-dependent kinase 12 Mus musculus 51-56 8239542-0 1993 Effect of DNA topoisomerase I inhibitor, 10-hydroxycamptothecin, on the structure and function of nuclei and nuclear matrix in bladder carcinoma MBT-2 cells. 10-hydroxycamptothecin 41-63 topoisomerase (DNA) I Mus musculus 10-29 8239542-1 1993 The effects of 10-hydroxycamptothecin (HCPT), a DNA topoisomerase I inhibitor, on the structure of nuclei and nuclear matrix and new DNA replication was investigated in murine bladder carcinoma MBT-2 cells. 10-hydroxycamptothecin 15-37 topoisomerase (DNA) I Mus musculus 48-67 8239542-1 1993 The effects of 10-hydroxycamptothecin (HCPT), a DNA topoisomerase I inhibitor, on the structure of nuclei and nuclear matrix and new DNA replication was investigated in murine bladder carcinoma MBT-2 cells. 10-hydroxycamptothecin 39-43 topoisomerase (DNA) I Mus musculus 48-67 34113937-1 2021 A blue light activated anti-cancer prodrug, NST, was designed based on a photoactive 4-aminonaphthalimide derivative and an anticancer drug, 10-hydroxycamptothecin. 10-hydroxycamptothecin 141-163 sulfotransferase family 4A member 1 Homo sapiens 44-47 32061620-3 2020 Here we fabricated a tumor microenvironment-activated self-targeting nanodrug, via co-assembly of hydroxycamptothecin (HCPT) and bi-functional methotrexate (MTX, not only has antitumor effect but also shows innate affinity towards folate receptors) followed by surface covering through acidity-responsive polyethylene glycol (PEG). 10-hydroxycamptothecin 119-123 metaxin 1 Homo sapiens 157-160 32061620-4 2020 Notably, the morphology and size of MTX-HCPT nanodrug could be tuned by varying the drug-to-drug ratio and assembly time. 10-hydroxycamptothecin 40-44 metaxin 1 Homo sapiens 36-39 31621074-0 2020 AMPK-mTOR-ULK1 axis activation-dependent autophagy promotes hydroxycamptothecin-induced apoptosis in human bladder cancer cells. 10-hydroxycamptothecin 60-79 protein kinase AMP-activated catalytic subunit alpha 2 Homo sapiens 0-4 31621074-0 2020 AMPK-mTOR-ULK1 axis activation-dependent autophagy promotes hydroxycamptothecin-induced apoptosis in human bladder cancer cells. 10-hydroxycamptothecin 60-79 mechanistic target of rapamycin kinase Homo sapiens 5-9 31621074-0 2020 AMPK-mTOR-ULK1 axis activation-dependent autophagy promotes hydroxycamptothecin-induced apoptosis in human bladder cancer cells. 10-hydroxycamptothecin 60-79 unc-51 like autophagy activating kinase 1 Homo sapiens 10-14 32057901-10 2020 Finally, we found that chemotherapy drug hydroxycamptothecin (HCPT) could decrease Arl4c expression levels by inhibiting the activation of the AKT pathway in A549 and 95-D cells. 10-hydroxycamptothecin 41-60 ADP ribosylation factor like GTPase 4C Homo sapiens 83-88 32057901-12 2020 CONCLUSION: Here, we highlighted the AKT pathway as an important regulatory pathway for Arl4c expression in lung cancer cells and identified HCPT as a promising drug for lung adenocarcinoma treatment that functioned by targeting Arl4c expression. 10-hydroxycamptothecin 141-145 ADP ribosylation factor like GTPase 4C Homo sapiens 88-93 32057901-10 2020 Finally, we found that chemotherapy drug hydroxycamptothecin (HCPT) could decrease Arl4c expression levels by inhibiting the activation of the AKT pathway in A549 and 95-D cells. 10-hydroxycamptothecin 41-60 AKT serine/threonine kinase 1 Homo sapiens 143-146 32057901-12 2020 CONCLUSION: Here, we highlighted the AKT pathway as an important regulatory pathway for Arl4c expression in lung cancer cells and identified HCPT as a promising drug for lung adenocarcinoma treatment that functioned by targeting Arl4c expression. 10-hydroxycamptothecin 141-145 ADP ribosylation factor like GTPase 4C Homo sapiens 229-234 32057901-10 2020 Finally, we found that chemotherapy drug hydroxycamptothecin (HCPT) could decrease Arl4c expression levels by inhibiting the activation of the AKT pathway in A549 and 95-D cells. 10-hydroxycamptothecin 62-66 ADP ribosylation factor like GTPase 4C Homo sapiens 83-88 32057901-10 2020 Finally, we found that chemotherapy drug hydroxycamptothecin (HCPT) could decrease Arl4c expression levels by inhibiting the activation of the AKT pathway in A549 and 95-D cells. 10-hydroxycamptothecin 62-66 AKT serine/threonine kinase 1 Homo sapiens 143-146 32057901-11 2020 Moreover, accumulation of ubiquitinated Arl4c protein was increased by HCPT and LY294002 (an AKT inhibitor) treatment whereas the proteasome inhibitor MG-132 attenuated the inhibitory effect of HCPT and LY294002 on Arl4c expression. 10-hydroxycamptothecin 71-75 ADP ribosylation factor like GTPase 4C Homo sapiens 40-45 30720099-0 2019 10-Hydroxycamptothecin induces apoptosis in human fibroblasts by regulating miRNA-23b-3p expression. 10-hydroxycamptothecin 0-22 microRNA 23b Homo sapiens 76-85 32703132-3 2020 AIM: In this study, we developed a novel nanoliposome encapsulated 10-hydroxycamptothecin modified with glycyrrhetinic acid (GA) and TAT peptide (GA/TAT-HCPT-LP) for the treatment of HCC. 10-hydroxycamptothecin 67-89 tyrosine aminotransferase Homo sapiens 133-136 32703132-3 2020 AIM: In this study, we developed a novel nanoliposome encapsulated 10-hydroxycamptothecin modified with glycyrrhetinic acid (GA) and TAT peptide (GA/TAT-HCPT-LP) for the treatment of HCC. 10-hydroxycamptothecin 67-89 tyrosine aminotransferase Homo sapiens 149-152 31817790-3 2019 Although the anticancer activity of (S)-10-Hydroxycamptothecin (HCPT), a TOP I specific inhibitor, has been reported in various cancers, the effect of HCPT on esophageal cancer is yet to be examined. 10-hydroxycamptothecin 36-62 DNA topoisomerase I Homo sapiens 73-78 31642230-7 2019 CONCLUSION: The combination of 2-DG and HCPT can synergistically induce the apoptosis of breast cancer cells, which may be caused by inhibiting the energy generation of tumor cells, inhibiting the phosphorylation of Akt protein and enhancing the activity of caspase-3 protein. 10-hydroxycamptothecin 40-44 AKT serine/threonine kinase 1 Homo sapiens 216-219 31642230-7 2019 CONCLUSION: The combination of 2-DG and HCPT can synergistically induce the apoptosis of breast cancer cells, which may be caused by inhibiting the energy generation of tumor cells, inhibiting the phosphorylation of Akt protein and enhancing the activity of caspase-3 protein. 10-hydroxycamptothecin 40-44 caspase 3 Homo sapiens 258-267 31551777-10 2019 In addition, in vitro studies show that HCPT significantly inhibits fibroblast proliferation and induces apoptosis by reducing the expression of extracellular matrix (ECM) proteins COL3A1 and alpha-smooth muscle actin (alpha-SMA). 10-hydroxycamptothecin 40-44 collagen type III alpha 1 chain Rattus norvegicus 181-187 31551777-10 2019 In addition, in vitro studies show that HCPT significantly inhibits fibroblast proliferation and induces apoptosis by reducing the expression of extracellular matrix (ECM) proteins COL3A1 and alpha-smooth muscle actin (alpha-SMA). 10-hydroxycamptothecin 40-44 actin gamma 2, smooth muscle Rattus norvegicus 192-217 31551777-10 2019 In addition, in vitro studies show that HCPT significantly inhibits fibroblast proliferation and induces apoptosis by reducing the expression of extracellular matrix (ECM) proteins COL3A1 and alpha-smooth muscle actin (alpha-SMA). 10-hydroxycamptothecin 40-44 actin gamma 2, smooth muscle Rattus norvegicus 219-228 31551777-11 2019 Finally, we employed small interfering RNA (siRNA) to target inositol requiring kinase 1 (IRE1) and activated transcription factor 6 (ATF-6) to verify that the effect of inhibitory fibrosis of HCPT disappears after knockdown of ATF-6 and IRE1, thereby suggesting that an anti-fibrotic effect of HCPT is mediated by the ER-dependent apoptotic pathway. 10-hydroxycamptothecin 193-197 activating transcription factor 6 Rattus norvegicus 228-233 31151274-7 2019 In addition, the combined use of JGGC decreased the levels of LRP, P-gp and Bcl-2/Bax when treated with HCPT. 10-hydroxycamptothecin 104-108 low density lipoprotein receptor-related protein 1 Mus musculus 62-65 31151274-7 2019 In addition, the combined use of JGGC decreased the levels of LRP, P-gp and Bcl-2/Bax when treated with HCPT. 10-hydroxycamptothecin 104-108 phosphoglycolate phosphatase Mus musculus 67-71 31151274-7 2019 In addition, the combined use of JGGC decreased the levels of LRP, P-gp and Bcl-2/Bax when treated with HCPT. 10-hydroxycamptothecin 104-108 B cell leukemia/lymphoma 2 Mus musculus 76-81 31151274-7 2019 In addition, the combined use of JGGC decreased the levels of LRP, P-gp and Bcl-2/Bax when treated with HCPT. 10-hydroxycamptothecin 104-108 BCL2-associated X protein Mus musculus 82-85 31151274-9 2019 In summary, an increased concentration of HCPT in tissues was observed when it was combined with JGGC through inhibition of efflux protein, with a synergistic enhancement of the anticancer effect observed through promotion of apoptosis and immunity due to a reversion of the Th1/Th2 shift. 10-hydroxycamptothecin 42-46 negative elongation factor complex member C/D, Th1l Mus musculus 275-278 30720099-5 2019 In addition, the miR-23b-3p expression level in human fibroblasts was examined following HCPT treatment. 10-hydroxycamptothecin 89-93 microRNA 23b Homo sapiens 17-24 30720099-7 2019 The results demonstrated that HCPT treatment notably increased miR-23b-3p expression levels and accelerated fibroblast apoptosis. 10-hydroxycamptothecin 30-34 microRNA 23b Homo sapiens 63-70 30720099-8 2019 Therefore, upregulation of miR-23b-3p expression was demonstrated to promote fibroblast apoptosis, consistently with the effects of HCPT. 10-hydroxycamptothecin 132-136 microRNA 23b Homo sapiens 27-34 30720099-9 2019 The results of the present study indicated that HCPT may induce fibroblast apoptosis by regulating miR-23b-3p expression. 10-hydroxycamptothecin 48-52 microRNA 23b Homo sapiens 99-106 30221690-0 2018 Astragalus polysaccharide combined with 10-hydroxycamptothecin inhibits metastasis in non-small cell lung carcinoma cell lines via the MAP4K3/mTOR signaling pathway. 10-hydroxycamptothecin 40-62 mitogen-activated protein kinase kinase kinase kinase 3 Homo sapiens 135-141 30221690-0 2018 Astragalus polysaccharide combined with 10-hydroxycamptothecin inhibits metastasis in non-small cell lung carcinoma cell lines via the MAP4K3/mTOR signaling pathway. 10-hydroxycamptothecin 40-62 mechanistic target of rapamycin kinase Homo sapiens 142-146 30221690-3 2018 The present study examined the effects of Astragalus polysaccharide (APS) and 10-hydroxycamptothecin (HCPT), which are associated with marked suppression and dephosphorylation of the MAP4K3/mammalian target of rapamycin (mTOR) signaling pathway, in the H1299 NSCLC cell line. 10-hydroxycamptothecin 78-100 mitogen-activated protein kinase kinase kinase kinase 3 Homo sapiens 183-189 30221690-3 2018 The present study examined the effects of Astragalus polysaccharide (APS) and 10-hydroxycamptothecin (HCPT), which are associated with marked suppression and dephosphorylation of the MAP4K3/mammalian target of rapamycin (mTOR) signaling pathway, in the H1299 NSCLC cell line. 10-hydroxycamptothecin 78-100 mechanistic target of rapamycin kinase Homo sapiens 190-219 30221690-3 2018 The present study examined the effects of Astragalus polysaccharide (APS) and 10-hydroxycamptothecin (HCPT), which are associated with marked suppression and dephosphorylation of the MAP4K3/mammalian target of rapamycin (mTOR) signaling pathway, in the H1299 NSCLC cell line. 10-hydroxycamptothecin 78-100 mechanistic target of rapamycin kinase Homo sapiens 221-225 30221690-3 2018 The present study examined the effects of Astragalus polysaccharide (APS) and 10-hydroxycamptothecin (HCPT), which are associated with marked suppression and dephosphorylation of the MAP4K3/mammalian target of rapamycin (mTOR) signaling pathway, in the H1299 NSCLC cell line. 10-hydroxycamptothecin 102-106 mitogen-activated protein kinase kinase kinase kinase 3 Homo sapiens 183-189 30221690-3 2018 The present study examined the effects of Astragalus polysaccharide (APS) and 10-hydroxycamptothecin (HCPT), which are associated with marked suppression and dephosphorylation of the MAP4K3/mammalian target of rapamycin (mTOR) signaling pathway, in the H1299 NSCLC cell line. 10-hydroxycamptothecin 102-106 mechanistic target of rapamycin kinase Homo sapiens 190-219 30221690-3 2018 The present study examined the effects of Astragalus polysaccharide (APS) and 10-hydroxycamptothecin (HCPT), which are associated with marked suppression and dephosphorylation of the MAP4K3/mammalian target of rapamycin (mTOR) signaling pathway, in the H1299 NSCLC cell line. 10-hydroxycamptothecin 102-106 mechanistic target of rapamycin kinase Homo sapiens 221-225 29434958-0 2018 Anticancer effects of 10-hydroxycamptothecin induce apoptosis of human osteosarcoma through activating caspase-3, p53 and cytochrome c pathways. 10-hydroxycamptothecin 22-44 caspase 3 Homo sapiens 103-112 29406728-7 2018 Next, we selected two chemotherapeutic agents (10-hydroxycamptothecine and docetaxel) and a fluorescent dye (DiD) as payloads of PPR NPs and successfully demonstrated that this nanocarrier could efficiently deliver them into cell nuclei in a light-controlled manner. 10-hydroxycamptothecin 47-70 PPR1 Homo sapiens 129-132 29434958-0 2018 Anticancer effects of 10-hydroxycamptothecin induce apoptosis of human osteosarcoma through activating caspase-3, p53 and cytochrome c pathways. 10-hydroxycamptothecin 22-44 tumor protein p53 Homo sapiens 114-117 29434958-0 2018 Anticancer effects of 10-hydroxycamptothecin induce apoptosis of human osteosarcoma through activating caspase-3, p53 and cytochrome c pathways. 10-hydroxycamptothecin 22-44 cytochrome c, somatic Homo sapiens 122-134 29434958-6 2018 The anticancer effects of HCPT were demonstrated to significantly activate the protein expression of p53, PARP-1 and cytochrome c, and suppress Bcl-2 protein expression and promote the activity of caspase-9 and caspase-3 in human osteosarcoma cells. 10-hydroxycamptothecin 26-30 tumor protein p53 Homo sapiens 101-104 29434958-6 2018 The anticancer effects of HCPT were demonstrated to significantly activate the protein expression of p53, PARP-1 and cytochrome c, and suppress Bcl-2 protein expression and promote the activity of caspase-9 and caspase-3 in human osteosarcoma cells. 10-hydroxycamptothecin 26-30 poly(ADP-ribose) polymerase 1 Homo sapiens 106-112 29434958-6 2018 The anticancer effects of HCPT were demonstrated to significantly activate the protein expression of p53, PARP-1 and cytochrome c, and suppress Bcl-2 protein expression and promote the activity of caspase-9 and caspase-3 in human osteosarcoma cells. 10-hydroxycamptothecin 26-30 cytochrome c, somatic Homo sapiens 117-129 29434958-6 2018 The anticancer effects of HCPT were demonstrated to significantly activate the protein expression of p53, PARP-1 and cytochrome c, and suppress Bcl-2 protein expression and promote the activity of caspase-9 and caspase-3 in human osteosarcoma cells. 10-hydroxycamptothecin 26-30 BCL2 apoptosis regulator Homo sapiens 144-149 29434958-6 2018 The anticancer effects of HCPT were demonstrated to significantly activate the protein expression of p53, PARP-1 and cytochrome c, and suppress Bcl-2 protein expression and promote the activity of caspase-9 and caspase-3 in human osteosarcoma cells. 10-hydroxycamptothecin 26-30 caspase 9 Homo sapiens 197-206 29434958-6 2018 The anticancer effects of HCPT were demonstrated to significantly activate the protein expression of p53, PARP-1 and cytochrome c, and suppress Bcl-2 protein expression and promote the activity of caspase-9 and caspase-3 in human osteosarcoma cells. 10-hydroxycamptothecin 26-30 caspase 3 Homo sapiens 211-220 29434958-7 2018 In conclusion, the anticancer effects of HCPT appear to induce the apoptosis of human osteosarcoma cells through the activation of the caspase-3, p53 and cytochrome c pathways. 10-hydroxycamptothecin 41-45 caspase 3 Homo sapiens 135-144 29434958-7 2018 In conclusion, the anticancer effects of HCPT appear to induce the apoptosis of human osteosarcoma cells through the activation of the caspase-3, p53 and cytochrome c pathways. 10-hydroxycamptothecin 41-45 tumor protein p53 Homo sapiens 146-149 29434958-7 2018 In conclusion, the anticancer effects of HCPT appear to induce the apoptosis of human osteosarcoma cells through the activation of the caspase-3, p53 and cytochrome c pathways. 10-hydroxycamptothecin 41-45 cytochrome c, somatic Homo sapiens 154-166 28097065-0 2017 Upregulation of NOXA by 10-Hydroxycamptothecin plays a key role in inducing fibroblasts apoptosis and reducing epidural fibrosis. 10-hydroxycamptothecin 24-46 phorbol-12-myristate-13-acetate-induced protein 1 Rattus norvegicus 16-20 28097065-6 2017 Our results showed that HCPT could induce apoptosis in fibroblasts and up-regulate the expression of NOXA. 10-hydroxycamptothecin 24-28 phorbol-12-myristate-13-acetate-induced protein 1 Rattus norvegicus 101-105 28097065-11 2017 Also, immunohistochemical staining showed that the expression of NOXA increased as the concentrations of HCPT increased. 10-hydroxycamptothecin 105-109 phorbol-12-myristate-13-acetate-induced protein 1 Rattus norvegicus 65-69 28097065-12 2017 Our findings are the first to demonstrate that upregulation of NOXA by HCPT plays a key role in inducing fibroblast apoptosis and in reducing epidural fibrosis. 10-hydroxycamptothecin 71-75 phorbol-12-myristate-13-acetate-induced protein 1 Rattus norvegicus 63-67 27721159-0 2017 Chemosensitizing effect of Paris Saponin I on Camptothecin and 10-hydroxycamptothecin in lung cancer cells via p38 MAPK, ERK, and Akt signaling pathways. 10-hydroxycamptothecin 63-85 mitogen-activated protein kinase 14 Homo sapiens 111-114 27721159-0 2017 Chemosensitizing effect of Paris Saponin I on Camptothecin and 10-hydroxycamptothecin in lung cancer cells via p38 MAPK, ERK, and Akt signaling pathways. 10-hydroxycamptothecin 63-85 mitogen-activated protein kinase 1 Homo sapiens 121-124 27721159-0 2017 Chemosensitizing effect of Paris Saponin I on Camptothecin and 10-hydroxycamptothecin in lung cancer cells via p38 MAPK, ERK, and Akt signaling pathways. 10-hydroxycamptothecin 63-85 AKT serine/threonine kinase 1 Homo sapiens 130-133 27721159-4 2017 Mechanism study indicated that PSI improved the CPT/HCPT induced apoptosis in lung cancer cells through mitochondria pathway including cytochrome C release and activation of caspase-9 and -3 cascades. 10-hydroxycamptothecin 52-56 cytochrome c, somatic Homo sapiens 135-147 27721159-6 2017 Moreover, PSI enhanced CPT/HCPT-mediated inhibition of p38 MAPK and activation of phosphorylation of p38 MAPK in H1299 cells, and suppression of Akt and ERK pathways activation in H460 cells as well as in H446 cells. 10-hydroxycamptothecin 27-31 mitogen-activated protein kinase 14 Homo sapiens 55-58 27721159-6 2017 Moreover, PSI enhanced CPT/HCPT-mediated inhibition of p38 MAPK and activation of phosphorylation of p38 MAPK in H1299 cells, and suppression of Akt and ERK pathways activation in H460 cells as well as in H446 cells. 10-hydroxycamptothecin 27-31 mitogen-activated protein kinase 14 Homo sapiens 101-104 27721159-6 2017 Moreover, PSI enhanced CPT/HCPT-mediated inhibition of p38 MAPK and activation of phosphorylation of p38 MAPK in H1299 cells, and suppression of Akt and ERK pathways activation in H460 cells as well as in H446 cells. 10-hydroxycamptothecin 27-31 mitogen-activated protein kinase 1 Homo sapiens 59-63 27878232-7 2017 This is the first report on the sensitivity to hydroxycamptothecine, cis-dichlorodiamineplatinum and gemcitabine that increased after knockdown of bleomycin hydrolase at protein level. 10-hydroxycamptothecin 47-67 bleomycin hydrolase Homo sapiens 147-166 26744836-10 2016 Our data revealed that CPT, 10-hydroxycamptothecin (HCPT), 10-methoxycamptothecin (MCPT) and 9-nitrocamptothecin (9NC) significantly inhibit the uptake activity of OAT3. 10-hydroxycamptothecin 28-50 solute carrier family 22 member 8 Homo sapiens 164-168 27912880-11 2016 Combination treatment of BA and HCPT induced BGC823 cells apoptosis mainly via intrinsic rather than extrinsic pathways, and preferentially arresting cell cycle in G1 and G2 phases with the aid of p21. 10-hydroxycamptothecin 32-36 H3 histone pseudogene 16 Homo sapiens 197-200 27912880-15 2016 CONCLUSION: HCPT and BA, a new and effective combination therapy, synergistically target Topo I and up-regulate p53 to induce cell apoptosis and cell cycle arrest. 10-hydroxycamptothecin 12-16 tumor protein p53 Homo sapiens 112-115 26744836-10 2016 Our data revealed that CPT, 10-hydroxycamptothecin (HCPT), 10-methoxycamptothecin (MCPT) and 9-nitrocamptothecin (9NC) significantly inhibit the uptake activity of OAT3. 10-hydroxycamptothecin 52-56 solute carrier family 22 member 8 Homo sapiens 164-168 27470413-12 2016 Amazingly, Ch-1 at non-toxic concentration (2.5-10muM) enhanced significantly anti-cancer effect of 10-hydroxy camptothecin (HCPT) on Hela, BGC823, and MCF-7 cells. 10-hydroxycamptothecin 100-123 SUN domain containing ossification factor Homo sapiens 11-15 27470413-12 2016 Amazingly, Ch-1 at non-toxic concentration (2.5-10muM) enhanced significantly anti-cancer effect of 10-hydroxy camptothecin (HCPT) on Hela, BGC823, and MCF-7 cells. 10-hydroxycamptothecin 125-129 SUN domain containing ossification factor Homo sapiens 11-15